Photo: ca.finance.yahoo.com
Former FDA vaccine chief Peter Marks joins Eli Lilly
Peter Marks, the former FDA vaccine chief, has joined Eli Lilly to lead efforts in molecule discovery and infectious diseases following his ousting earlier this year.
- Peter Marks, previously the director of the FDA's Center for Biologics Evaluation and Research, was removed from his position earlier this year amid scrutiny over vaccine approvals.
- At Eli Lilly, Marks will focus on advancing research in molecule discovery and addressing infectious diseases, which are critical areas in pharmaceutical innovation.
- Eli Lilly's hiring of Marks underscores the company's commitment to enhancing its vaccine and infectious disease portfolio in a competitive biopharmaceutical landscape.
Why It Matters
Marks' transition from the FDA to Eli Lilly highlights the ongoing battle in public health and vaccine development, particularly as pharmaceutical companies ramp up efforts to combat emerging infectious diseases.